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Abstract
Charcot neuropathic osteoarthropathy (CN) is a rare disease (NIDDK, NIH Summary Report Charcot Workshop, 2008)
that causes significant morbidity and mortality for affected patients. The disease can result in severe deformities of
the foot and ankle that contribute to the development of ulcerations and amputations. Medical advances have
failed to find ways to stop the progression of the disease. However, it is known that early detection of the CN has a
substantial impact on patient outcomes. CN in the earliest stage is very difficult to recognize and differentiate from
other similar presenting diseases. We intend to outline clinical considerations practitioners can use when evaluating
a patient with early stage suspected CN.
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Background
The development of Charcot neuropathic osteoarthropa-
thy (CN) which is rare [1] in the foot and/or ankle can
lead to both structural and functional abnormalities
resulting in ulcerations. Once ulcerations occur there is
a higher risk for amputation. CN is also an independent
risk factor for mortality [2, 3] (Table 1). It has been dem-
onstrated CN diagnosis can be missed by referring phy-
sicians 95 % of the time prior to referral to a foot
specialist [4]. CN that is identified after 8 weeks can
have complications such as deformity at a rate of 67 %.
CN that is identified within 4 weeks of onset has a com-
plication rate of only 14 % [4]. Therefore, clinicians who
make the diagnosis of CN early can have a great impact
on the morbidity and mortality outcome of their patients
with the disease.
This article will attempt to outline processes that clini-
cians can use to diagnose CN when it is in its early stage
and future consideration for diagnoses targets.
Main text
Charcot neuropathic osteoarthropathy can be missed by
95 % of providers prior to foot specialist referral [4]. Be-
cause Endocrinology uniquely situates the physician with
many patient encounters involving patients with diabetes
mellitus, it is critical for the specialty to be well aware of
the signs and symptoms of Stage 0 CN. Stage 0 CN, a
prodromal state of the disease, occurs when a foot dem-
onstrates changes including redness, swelling, warmth,
and pain, signs typically representing inflammation, in
the neuropathic patient. These signs and symptoms are
antecedent to foot architecture breakdown, seen in the
later stages of CN. One of the most widely used CN
classification system was proposed by Eichenholtz [5].
Stage 1 represents development, characterized by osse-
ous debris, fragmentation, disruption, and dislocation
seen of involved joints. In Stage 2, also known as the
stage of coalescence, sclerosis, absorption of fine debris,
and fusion of most large osseous fragments is seen.
Lastly, in stage 3, the reconstruction and reconstitution
stage, sclerosis becomes less, the major fragments are
rounded and there is attempt at reformation of joint
architecture [5]. Unfortunately, this classification system
did not attempt to describe the prodromal phase and
misses the earliest inflammatory phase.
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Conducting a search in PubMed/NCBI, Google Scholar,
and Cochrane Databases for Stage 0 CN symptoms reveals
a paucity of published studies on the specific subject.
Shibata [6], and later Sella [7], were the first to describe
changes associated with Stage 0 CN in leprotic and dia-
betic patients, respectively. As far as we are aware, no
paper describes the methodology to accurately diagnose
Stage 0 CN patients and refer to a foot specialist. This lack
of discussion about Stage 0 CN gives reason to present up
to date information about CN to those most likely to en-
counter the Stage 0 CN patient. We also stress that CN
needs to be included in the differential diagnosis for
neuropathic patients that present with newly onset red,
hot, swollen foot because if it not, it often goes misdiag-
nosed [8–11]. In this review article, we will further define
stage 0 and give the practicing endocrinologist pragmatic
tools to appropriately identify CN and refer to a foot spe-
cialist for further management.
Epidemiology and pathophysiology
Charcot neuropathic osteoarthropathy is a rare destructive
disease with a prevalence of 0.1 %-0.9 % [12–14] (Table 2).
Although the true etiology of CN is unknown, it is accepted
that neuropathy precedes the disease. In a conceptual
model proposed by Koeck, et al [15], important
components include neurotrophic, microtrauma, and neu-
rovascular effects [15] including a stage of pro-
inflammatory cytokine activity of with pro-inflammatory
cytokines, such as elevated Tissue Necrosis Factor alpha
[16]. (TNF α) and Receptor Activator Nuclear Factor K lig-
and (RANKL) [8] (Table 3).
Table 1 Characteristic data and analysis for patients with undetected early Charcot neuroarthropathy
Group I Group II Mann–Whitney U test P-value
n 7 15
Age 62.3 53.5
Follow up (Weeks) 49.9 +/− 21.7 114.4 +/− 58.8
Time to correct diagnosis (weeks) 4.1 +/− 0.7 8.7 +/− 6.8 24.5 0.0262
Time from stage 0 to active Charcot (weeks) 10.9 +/− 7.5
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*Group I includes patients who did not progress to active Charcot foot
*Group II includes patients who did progress to active Charcot foot
Adapted from Wukich et al [4]. Characteristics from a population of people with early Charcot foot that either progressed to active CN or did not. The Group
(Group II) who progressed to active CN endured a significant difference in overall complications and were diagnosed with CN much later than the group who did
not progress to active Charcot foot (Group I)
Table 2 Incidence of Charcot Neuroarthropathy in Patients with
Diabetes




Sinha et al. 1971 [55] 101 (N/A) 0.1 %
Cofield et al. 1983 [56] 96 (116) 7.5–29 %
Sella et al. 1999 [7] 40 (51) 5 %
Fabrin and Holstein 2000 [13] 115 (140) 0.3 %/year
Sanders et al. 2001 [57] N/A 0.1–7.5 %
Rajbhandari 2002 [58] N/A 0.1–0.4 %
Hartemann-Heurtier et al. 2002 [59] N/A 0.2–3 %
Lavery et al. 2003 [14] N/A 0.0085 %/year
Adapted from Frykberg, R and Belczyk, R [17]. A brief review of the literature
demonstrating the relative low incidence of CN in the overall population.
There is a range of incidences reported from 0.10 to 29.00 % and seems
consistent over time
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Risk factors for Charcot
Clinicians can begin to develop a picture for the patient
who presents with CN by being familiar with the risk fac-
tors. Risk factors for CN include, advanced age, male gen-
der, white race, lower educational level, body mass index
(BMI), duration of diabetes, peripheral neuropathy, de-
creased bone mineral density (BMD), and a history of pan-
creas and/or kidney transplant surgery [17]. Other risk
factors identified using VA administrative data include: el-
evated HbA1c, renal failure, rheumatoid arthritis, iron
deficiency anemia and obesity [2]. Petrova et al. in 2005
[18] also noted the relationship between patients with
osteopenia and CN. There has also been a documented
correlation between CN and patients that with end-stage
kidney disease and renal transplantation [19, 20]. As a rare
disease, it can be very useful to look use big data science
methodologies to elucidate previously unknown risk fac-
tors for the CN. Large databases with hundreds of thou-
sands of diabetics can be mined to identify large enough
numbers with CN to better understand the epidemiology,
Table 3 Etiology of CN Model Proposed by Koeck et al
Skin (OA) Skin (CN) Synovium (OA) Synovium (CN) Bone (OA) Bone (CN)
























Density of Substance P Nerve Fibers and Sympathetic Nerve Fibers in Skin, Synovium, and Bone of Patient’s with Charcot Neuroarthropathy and Osteoarthritis
Table is adapted from Koeck et al [56]. In their study they demonstrated that the Charcot joint (synovium) demonstrates a lack of sympathetic control compared to the
control sample of patients with osteoarthritic joints. Here we report the approximate mean from their study to demonstrate the difference. The p-value between synovium
concentration of sympathetic nerve fibers is <0.006 and indicates a significant difference between the two conditions. It was the only difference between the two groups that
was significant
Fig. 1 Reproduced with permission from Munson et al [21]. Association diagram showing the clinical milieu in which CN (pink node in center of
square) often exists. Each node represents an ICD-9 code, with the size of the node proportional to its frequency in the overall dataset, and node colors
representing high-level clinical categories (see legend). Edges between nodes represent highly significant associations. Arrowheads show temporality
with preceding nodes pointing to subsequent nodes. This figure was made using the following criteria: Association p-value < 1.0 × 10-176; association
odds ratio > 200; temporal p-value < 1.0 x 10-6. The two red nodes directly pointing to Charcot foot are related to type 2 diabetes (ICD-9 codes 250.60
and 250.90)
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risk factors, and management of these patients. For ex-
ample, Munson and colleagues used a data mining ap-
proach to identify 710 associations of different medical
conditions with CN with 111 having temporal associations
with the development of CN [21] (Fig. 1).
Amputation risk
Charcot neuropathic osteoarthropathy increases the af-
fected patient’s risk of foot ulcer by more than 30-fold,
with 63 % of persons with Charcot foot eventually de-
veloping foot ulcer [2]. Using Medicare data Wrobel
and Mayfield demonstrated that diabetes increases the
risk of major amputation by 10-fold [22]. According to
Sohn et al. 2010, the risk of amputation in those pa-
tients with Charcot foot is 6.6 % in the community, and
more than double in VA patients at 14.7 %. However,
when Charcot Foot occurs with foot ulcer, the patient
is at a 12-fold higher risk of amputation than patients
with Charcot alone [23]. Charcot Foot has also been de-
scribed to be an independent risk factor for mortality
after controlling for foot ulcer and other comorbid con-
ditions [2].
Rogers and Bevilacqua describe an amputation clas-
sification risk scheme illustrating how as Charcot
deformity, ulceration and osteomyelitis approach the
proximal foot and ankle, amputation risk increases [24]
(Table 4).
Differential diagnosis
Frequent misdiagnosis has been reported with condi-
tions such as cellulitis, gout, deep-vein thrombosis
(DVT), osteomyelitis [9], or even osteoarthritis [8]. Cli-
nicians must have a high index of suspension for
neuropathic patients presenting with Charcot stage 0.
The addition of Charcot foot to their list of differential
diagnosis for patients with the classic red, hot, swollen
foot may help decrease the number of missed cases. It
is important to note that patients frequently present
with varying degrees of swelling, warmth and redness.
Minor trauma should not be dismissed. Charcot Foot
may also be preceded by events of foot surgery in
22 % of cases [10] and injuries such as ankle sprains
[11].
Clinical assessment
A. Recognition of Stage 0
Another important step in identifying CN is the cli-
nician’s ability to recognize stage zero. Most clinicians
have been trained to use radiographs to screen and
diagnosis the Charcot foot but waiting for radio-
graphic changes may result in increased comorbidity
for patients. Historically, clinicians refer to the
Eichenholtz classification which describes three stages
of Charcot using radiographs [5]. Stage I, the develop-
mental stage; bone fragmentation, osseous debris, os-
seous fragmentation, and disruption or dislocation of
joints were noted radiographically. Stage II, the stage
of coalescence; there was sclerosis, absorption of bone
fragments and fusion of most large fragments was
noted to adjacent bone. Stage III, the stage of recon-
struction and reconstitution; there is lessened scler-
osis, remodeling and rounding of bone ends, with an
attempt at reformation of joint architecture [5]. Shi-
bata et al. described CN Stage 0 in 1990 in which was
the clinical presence of swelling, erythema and
warmth in the presence of normal radiographs in pa-
tients with leprotic neuroarthropathy [6]. In 1999
Sella and Barette described stage 0 in patients with
CN [7] (Table 5). This prodromal phase is antecedent
to foot architecture breakdown with inflammation
seen clinically.
B. Anatomic Location
Charcot neuropathic osteoarthropathy typically affects
the midfoot. Several authors have described the ana-
tomic location is associated with CN. One of the most
Table 4 Amputation Risk Rogers & Bevilaqua
A combined anatomic and complexity classification of Charcot neuroarthropathy
Adapted from Rogers and Belivqua [60]. Using both an anatomic model combined with level of complexity, it is clearly demonstrated that as one
progresses both proximal (to the right on the graph) in anatomic location and/or toward osseous involvement (down on the graph), the risk of major
amputation increases
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recognized classification is the Sanders classification
which it clearly highlights the midfoot as the most tar-
geted area for Charcot development [25–27] (Fig. 2). It
has been hypothesized that limited ankle joint range of
motion coupled with neuropathy and obesity may pre-
dispose the mid-foot for breakdown.
C. Temperature Gradient and Other Clinical Signs
The clinical presentation of CN stage 0 is character-
ized by an edematous, erythematous warm foot. Some
discussion is necessary to quantify the temperature in-
crease. Armstrong and Lavery reported the baseline
Table 5 Recognition of stage 0: Sella & Barrette Staging of Charcot
Stage Diagnosis
0 Localized heat and midfoot swelling
1 Localized osteoporosis, subchondral cysts, erosions, and diastasis
2 Joint subluxations
3 Joint dislocations
4 Sclerosis and ultimate fusion of involved joint
Stage No. of Feet Radiographs Scans – Tc99 Scan- In/Ga Clinical Findings
0 10 Negative + - Increased heat
1 6 Cysts, erosions, diastasis + - Increased heat and swelling
2 16 Joint subluxation + -/less + Mild pronation
3 12 Joint dislocation + -/less + Bony prominences, pronation, rocker bottom
4 7 Joint Fusions and Sclerosis - - Rocker bottom, bony prominences, pronation
Staging for Charcot Foot from Sella and Barrette
Adapted from Sella and Barette [7]. A simple classification of patient with different stages of CN with associated symptomatology and clinical, radiographic, and
nuclear scan findings. This study involved a group of 51 feet with diagnosed CN
Fig. 2 Adapted from Rogers and Frykberg [27] Staging of the Charcot foot based on anatomic location within the foot. Five anatomic patterns
are represented with pattern I affecting the phalanges, IPJs, MTPJs and distal metatarsal bones with atrophic and destructive changes; pattern II
affecting the tarsometatarsal joints (Lisfranc’s joint) often with ulceration at apex of collapsed cuneiforms of cuboid; pattern III affecting the
naviculocuneiform, talonavicular, and calcaneocuboid joints (Chopart’s joint) with fragmentation of the NC joint and/or subluxation of the CC and
TN joints, pattern IV representing the talocrural joint (Ankle joint) and subtalar joints, and pattern V representing involvement of only the
calcaneal bone, and particularly avulsion of the posterior tuber of the calcaneus
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infrared dermal thermometry results for 39 patients pre-
senting with unilateral acute Charcot foot [28] After
15 min’ rest, they found an average 8.8 ± 2.3 °F higher
temperature compared to the contralateral joint of inter-
est (JOI). In a separate study, the same team reported
specific mean joint differences of 7.3 °F, 8.0 °F, and 8.8 °F
for the ankle Chopart, and Lisfranc’s joint respectively
[28, 29]. The temperature differences were found to
correlate highly with radiographic changes [28] and with
markers of bone turnover [30]. In the diabetic foot, stat-
ically measured joint risk factors may not be associated
with dynamic activity [31]. Najafi and colleagues studied
15 patients with acute CN and 17 patients with diabetes-
related peripheral neuropathy. At baseline the CN pa-
tients demonstrated a significant 1.84 +/− 1.3C
temperature difference between the affected and un-
affected foot. This difference is below the threshold for
both diagnosing and treating CN [30]. While significant,
this difference was less than 4.1C – 4.9C difference
found by Armstrong and Lavery [32]. Following walking
of 50 steps and 150 steps, the baseline temperature dif-
ferences between feet increased significantly by 60 %
[33]. As most bouts of activity for patients with
diabetes-related peripheral neuropathy are 50 steps or
less [34], dynamic temperature testing may be clinically
important. CN findings are typically unilateral. Pedal
pulses may be palpated in circumstances where there is
not marked edema.
D. Laboratory testing
While there is no definitive or specific laboratory
marker to diagnose CN, patients with CN may have
leukocytosis, elevated hsCRP and ESR as seen with other
inflammatory conditions. Hemoglobin A1C elevation
of > 7 % is common [35]. In instances where CN is one
of the differential diagnoses elevated uric acid levels may
be necessary to determine if a patient has gout. Clinical
evaluation for inflammation is paramount in diagnosis.
E. Histology to Confirm Charcot Neuropathic
Osteoarthropathy
It is also important to remember that in circumstances
where a biopsy can be performed that may be beneficial to
differentiate between other disease processes such as osteo-
myelitis. In patients with a normal joint, the articular cartil-
age is smooth, chondrocytes line up in regular rolls and
subchondral cancellous bone is intact. In joints affected by
CN there are degenerating fibrillary remains of cartilage,
absence of cartilage, and fibro osseous tissue [36]. La
Fontaine et al. characterized the CN bone further [37].
These authors illustrate that CN bone histology has charac-
teristics of reactive bone with presence of woven bone that
was immature and structurally disorganized. Further the
bone marrow spaces were infiltrated with hypervascular,
myxoid tissue with spindle fibroblasts with an increase in
Fig. 3 Histology Slides demonstrating histologic changes seen in patient with Charcot Neuroarthropathy [36]. The figure on the left demonstrates a
normal joint; here it is a distal interphalangeal joint. Note the smooth cartilage surface, organization of the chondrocytes in regular rows, and the
subchondral cancellous bone is intact. The figure on the right demonstrates a joint afflicted by CN. Note the absence of cartilage and replacement
with fibro-osseous tissue. The major histologic changes are evident at the joint, as demonstrated in the normal and pathologic samples above
Table 6 Chantelau and Grutznel MRI Classification of the Charcot Foot
Low Severity (without cortical fracture) High Severity (with cortical fracture)
Active Arthropathy Mild inflammation/edema No skeletal deformity X-ray is
otherwise normal MRI: Abnormal with edema,
microfractures and bone bruise
Severe edema/inflammation Severe Skeletal deformity
Microfractures on X-ray MRI: Abnormal with edema,
macrofractures and bone bruise
Inactive Arthropathy No inflammation No skeletal deformity X-ray is otherwise
normal MRI: No significant edema
No inflammation Skeletal deformity X-ray with past
macrofractures MRI: No significant edema
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the number of Howship’s lacunae and a decreased number
of osteocytes. This was less than that observed in both the
normal and DM groups of the study [37] (Fig. 3).
F. Imaging Modalities used to diagnose Charcot
Utilization of radiographs alone to determine the onset
of Charcot foot is not advised. We suggest that clinicians
utilize clinical judgment and consider other modalities
in addition to radiographs to diagnose CN in its earliest
stage. Radiographs should be performed to scrutinize
later stages of CN where fragmentation, fracturing, dis-
locations and effusions of joints exist. A MRI is superior
to a radiograph to diagnose CN Stage 0. We recognize
that there are instances where clinical judgment super-
sedes the need for a MRI. There are also circumstances
where MRI may not be the most cost-effective or patient
friendly based on other disease states such as a
diminished kidney function. However, MRI can detect
bone marrow edema and is therefore far more sensitive
and specific then a radiograph in the detection of Char-
cot earliest stage.
In April 2014 Chantelau and Grutzner [38] proposed a
new classification for CN which includes both clinical,
MRI, and radiographic as well as histologic findings.
This classification system seems to be the most current
in utilizing all of the current tools for diagnosing Char-
cot in its earliest phase and throughout the entire course
of the disease recognizing both the active and inactive
stages of involvement (Tables 6 and 7).
Bone scanning can be a useful tool in differentiation of
Charcot neuropathic osteoarthropathy with and without
osteomyelitis. It however must be used with caution be-
cause leukocyte labeled scintigraphy does not always
demonstrate changes where bony turnover is occurring.
Poor sensitivity is often attributable to chronicity of in-
fection, while poor specificity is attributable to nonspe-
cific inflammatory changes [39]. It must be stated that in
the earliest stages of Charcot, many polymorphonuclear
cells (PMNs) are present with acute inflammation [40].
The scans are therefore useful early to the astute phys-
ician and can demonstrate changes in tissue activity in a
day as compared to 10–14 days with standard radio-
graphs. With the development and addition of several
tags to the leukocyte and regardless of the exact under-
standing of the mechanism why labeled leukocytes
accumulate in the uninfected Charcot neuropathic
joint [41, 42] bone scanning can continue to be a
useful non-invasive imaging modality to differentiate
between the diagnosis of Charcot neuropathic osteoar-
thropathy and osteomyelitis.
Table 7 Combined Clinical symptoms, Advanced Imaging and Histopathology Classification
Clinical Signs and
Symptoms
CT and MRI features Histopathology
Active stage,
grade 0
Mild inflammation but no
gross deformity
Obligatory: diffuse BMO and STO (Kiuru Grade I–III), No
cortical disruption. Facultative: subchondral trabecular
microfractures (bone bruise); ligament damage
Lamellar bone with active surface. Remodelling
of trabeculae associated with microfractures.






Obligatory: fracture(s) with cortical disruption, BMO and
STO (Kiuru grade IV). Facultative: osteoarthritis, cysts,
cartilage damage, osteochondrosis, joint effusion, fluid
collection, bone erosion/necrosis, bone lysis, debris,
bone destruction, joint luxation/subluxation, ligament
damage, tenosynovitis, bone dislocation.
Increased vascularity of the marrow space, active
remodelling of woven bone. Compatible with
response to (impaction) fracture. Osteonecrosis.
Thickened synovium, fragmented cartilage and




No inflammation, no gross
deformity.
No abnormal imaging, or minimal residual BMO;
subchondral sclerosis, bone cysts, osteoarthrosis,
ligament damage
Sclerosis of bone characterized by broad lamellar
trabeculae with collagenous replacement and a






Residual BMO, cortical callus (Kiuru grade IV); joint
effusion, subchondral cysts, joint destruction, joint
dislocation, fibrosis, osteophyte formation, bone
remodelling, cartilage damage, ligament damage,
bone sclerosis, ankylosis, pseudoarthrosis
Woven bone, immature and structurally
disorganized, fibrosis
Adapted from Chanetelau and Gruetzner [38] classification of the Charcot foot using MRI to differentiate between high and low severity in active versus inactive
CN. The second table combines clinical, MRI, and histopathologic findings in accordance with Charcot foot severity
Table 8 Levels of Evidence (Miline) [50]
Level of Evidence Definition
I A systematic review of level II studies
II A randomized controlled trial
III A pseudorandomized controlled trial (alternate
allocation, etc.)
III-2 A comparative study with concurrent controls
(cohort, case–control)
III-3 A comparative study without concurrent control
(historical cohort)
IV Case Series
EO Expert Opinion – where evidence was absent
or unreliable and advice was formulated based
on clinical judgement of experts in the fields
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Historically, 99technetium-MDP, gallium-67 citrate, and
indium-111 played a role in the differentiation between
soft tissue infection and osseous infection [43]. Gallium
was used because it has high affinity toward inflammatory
processes but lacked affinity for osteoblastic activity. In-
dium had a longer half-life than gallium and had greater
specificity for infection because it depended on leukocyte
chemotaxis. However, these early scintigraphy agents were
not without fault because they had low specificity and
were effectively useless to differentiate certain conditions
[44]. Hexamethylptopyleneamine oxime (HMPAO or
Ceretec) is commonly used today to differentiate osteo-
myelitis from Charcot joint. Traditionally, the HMPAO la-
beled leukocytes are injected into the subject and a three
phase bone scan is performed at intervals as described as
blood flow, blood pool, and bony turnover stages as
Fig. 4 The pathogenesis of CN is multifactorial and not entirely determined. Neuropathy, inflammation, and hyperglycemia all play major roles in
CN development and progression. Peripheral neuropathy includes sensory, motor, autonomic, and neurogenic peptide dysregulation [52]. As a
result; the patient does not necessarily perceive traumatic events that could lead to areas of increase pressure and potential sites of breakdown
[53]. This perpetuates the inflammatory cycle, leading to a vicious cycle that intimately affects bony turnover [54]. The bony turnover is also
regulated by hyperglycemia which is shown to increase advanced glycation end products (AGEs). AGEs lead to an increase in receptor for AGEs
(RAGE). The increase in RAGE leads to an increase in RANK-L which promotes osteoclastogenesis [55]. Finally, newer evidence demonstrates the
Charcot neuroarthropathic joint itself is lacking sympathetic control and may allow for increase perfusion to the area [32]. This may also disturb
the bony turnover ratio leading to weakened demineralized bone
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Table 9 CN Stage 0 Evaluation Algorithm Part I
Differential Diagnoses Erythema Edema Warmth Pain Skin Break Temperature Difference (>4C) Peripheral Neuropathy
Gout + +/− + ++ - - -
DVT + + + +/− - - -
Cellulitis + + + + + - +/−
CN (stage 0) + + + +/− - + +
Fig. 5 CN Stage 0 Evaluation Algorithm Part II
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discussed by Thakur et al [45]. Once the scan has been
completed, the images are inspected at each stage for ac-
tivity in the affected area. If there is positive activity at
each stage, then the cellular activity is consistent with
osteomyelitis. In 2001, Boc et al. demonstrated that while
HMPAO was the most reliable non-invasive imaging
study that could be done for differentiating osteomyelitis
from Charcot foot changes, it was second to bone biopsy
because false positives do occur [46]. More recently, Mor-
bach et al. demonstrated MRI rather than plantar bone
scintigraphy was superior for detection of chronic osteo-
myelitis with sensitivity of MRI at 100 % and for bone
scintigraphy at 78.4 % [47].
The basis for the addition of sulfur colloid to a techne-
tium bone scan lies in that both sulfur colloid and leuko-
cytes have an affinity toward cellular activity in the bone
marrow. Accordingly, this should be done in concert with
another labeled leukocyte scan, but it is described as being
done one hour after completion of the three phase bone
scan [44]. Leukocytes are attracted to areas of infection
and sulfur colloid is not [48]. More important is that simi-
lar patterns are demonstrated on image comparison be-
tween healthy individuals and those with abnormalities
when using the sulfur colloid scan. When a patient has
osteomyelitis, there is a localized increase in leukocyte up-
take observed along with suppression of sulfur colloid
[49]. By utilizing this inherent advantage, when there is an
edematous foot with a question of infection or a Charcot
event, the addition of sulfur colloid to a technetium bone
scan can aide in the differentiation.
What does the evidence tell us as it relates to
diagnosing Charcot neuropathic
osteoarthropathy?
In 2003 Milne et al. reviewed [50] the level of evidence as
it relates to CN treatment and diagnoses. Magnetic reson-
ance imaging has a level III; nuclear medicine has a level
of evidence IV (Table 8). FDG-PET has a level of evidence
IV and bone biopsy has a level of evidence expert opinion.
We believe this indicates the need to conduct randomized
clinical trials in patients with Charcot foot.
The ADA consensus report performed by Rogers and
associates [3] illustrate an algorithm for diagnosis of CN.
Their algorithm clearly outlines the clinician starting with
a clinical suspicion of CN and navigating through x-rays,
MRI or other nuclear imaging based on the patient’s clin-
ical findings, diagnostic results followed by the response
to treatment.
Future considerations
The pathogenesis of Charcot neuropathic osteoarthropa-
thy (CN) is multifactorial and not entirely determined.
Neuropathy, inflammation, obesity, and hyperglycemia
all play major roles in CN development and progression.
Peripheral neuropathy includes sensory, motor, auto-
nomic, and neurogenic peptide dysregulation [51]. As a
result, the patient does not necessarily perceive trau-
matic events that could lead to areas of increase pressure
and potential sites of breakdown [52, 53]. This perpetu-
ates the inflammatory cycle, leading to a vicious cycle
that intimately affects bony turnover [54].
The bony turnover is also regulated by hyperglycemia
which is shown to increase advanced glycation end prod-
ucts (AGEs). AGEs lead to an increase in receptor for
AGEs (RAGE). The increase in RAGE leads to an increase
in RANK-L which promotes osteoclastogenesis [15]. Fi-
nally, newer evidence demonstrates the CN joint itself is
lacking sympathetic control and may allow for increase
perfusion to the area [18]. This may also disturb the bony
turnover ratio leading to weakened demineralized bone
(Fig. 4).
Conclusion
In summary it is important to note that each clinician
who evaluates a patient with CN has the opportunity to
substantially change the outcome in their patients. They
should start by having a high index of suspicion which
cannot occur unless the clinician adds CN to their list of
differential diagnosis when evaluating a patient with neur-
opathy, diabetes, and other listed risk factors. The ability
for the astute clinician to recognize stage zero is also piv-
otal as in terms of deformity prevention and long term
outcomes (Table 9 & Fig. 5.). Offload patient during evalu-
ation process to prevent structural damage. A wheelchair,
crutches, or a walking boot are all suitable options. Refer-
ral to foot specialists and implementation of diagnostic
tools in a timely fashion such as dermal temperatures in
joint regions of interest, radiographs, MRI, bone scan and
other modalities based on their facilities capabilities as
early as possible is also crucial. We hope that in the future
the diagnosis of Charcot neuropathic osteoarthropathy
will be simple, but until that time surveillance and on-
going discussions about how we can improve diagnostic
strategies is the key to limb preservation.
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